Brilliant Futures

CooperVision is pleased to launch the Brilliant Futures™ Myopia Management Programme, featuring the innovative MiSight® 1 day contact lenses.

Brilliant Futures™ seeks to introduces a new standard of care for children with myopia providing inclusive practice, child and parent support for compliance, satisfaction, clinical outcomes and long-term loyalty. Brilliant Futures™ is built around MiSight® 1 day contact lenses, with ActivControl™ Technology, which have been clinically proven to slow the progression of myopia in children as young as eight.

The programme features:

• Professional Accreditation Programme delivered through CooperVision’s online Learning Academy. The programme equips practitioners to understand, initiate and develop a myopia management practice ahead of gaining access to Brilliant Futures™.
• In-Practice Tools helping practitioners identify those children most at risk of developing myopia and sophisticated communication tools to aid the introduction and subsequent commitment to intervention.
• Messaging Portal, currently in development, is an innovative text-based user support system linking patients directly to practitioners to gauge their lens-use experience and identify support needs.

Myopic progression has been linked to significant eye-health and sight-threatening conditions later in life such as cataracts, retinal detachment, glaucoma and myopic maculopathy. The risk of these conditions multiplies as a prescription gets stronger.^{iii, iv}

This is echoed in the seminal World Health Organization (WHO) 2015 report that declared myopia is increasing globally at an alarming rate, leading to significant increases in the risks for vision impairment from pathologic conditions associated with high myopia.^v

According to recent studies, children in the UK are becoming myopic at a younger age, and the proportion of children with myopia has more than doubled over the last 50 years in those aged between 10–16 years.^vi

CooperVision’s research into MiSight® 1 day’s effectiveness has been the longest continuous soft contact lens study for myopia management. The prospective, multi-centre, double-masked, randomised multi-year study enrolled 144 myopic children aged 8-12 years from Singapore, Canada, the United Kingdom and Portugal. Three-year peer-reviewed results published in Optometry and Vision Science in August 2019 indicated that use of MiSight® 1 day was shown to slow myopia progression by 59% on average as measured by mean cycloplegic spherical equivalent (SE) and 52% on average as measured by mean axial elongation of the eye.ⁱ

The trial has continued with highly encouraging results reported for years four and five, in which the original control group was refitted into MiSight® 1 day with some children wearing the contact lens in their late teens.^vii

“Myopia management is about going beyond vision correction and providing longer-term benefits to young patients,” said Indie Grewal, Optometrist and President of the British Contact Lens Association (BCLA). “This innovative approach has the potential to revolutionise clinical outcomes and can allow us to change the trajectory of childhood myopia in practice. We now have an opportunity to tackle myopia head-on and ultimately help young patients see well into the future.”

Start changing the course of childhood myopia today at coopervision.co.uk/practitioner/clinical-resources/myopia-in-children

---

ⁱ Chamberlain P, et al. Optom Vis Sci. 2019;96:556–567
ⁱⁱ Tideman J, et al. JAMA Opthalmol. 2016;134:1355-1363
ⁱⁱⁱ Flitcroft, D. Prog Retin Eye Res. 2012;31(6):622-60
^iv Bourne R, et al. Lancet Glob Health. 2013;1(6):e339-49
^v The Impact of Myopia and High Myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia. University of New South Wales, Sydney, Australia. 16-18 March 2015
^vi McCullough S, et al. PLoS ONE. 2016;11: e0146332
^vii Chamberlain P, et al. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens. 5-year results (2019 BCLA Clinical Conference & Exhibition).